Pfizer Vizimpro (dacomitinib) recommended by UK regulators to treat NSCLC

recentdays, Pfizer's Vizimpro (dacomitinib) has been recommended by regulators in the UK as a first-line treatment option for patients with late-stage or metastatic non-small cell lung cancer (NSCLC)about Vizimpro
Vizimpro is an oral, daily pan-human epidermal growth factor receptor (pan-EGFR) tyrosine kinase inhibitor (TKI)In the United States, Vizimpro was approved at the end of September 2018 for first-line treatment in patients with metastatic NSCLC who were confirmed to be present with EGFR No19 exon deficiency or 21 exon L858R displacement mutationVizimpro was approved for listing by the European Commission in April 2019In addition, Vizimpro has been approved by Japanese regulators for use in patients with EGFR mutation-positive, non-rectructable or recurrent NSCLCVizimpro is priced in the UK for 30 capsules per pack, priced at 2,703 pounds, but(http://offer a confidential discount to the NHSAbout ARCHER 105
Vizimpro's approval is based on data from phase III clinical studies of ARCHER 1050The study, a randomized, open label, head-to-head study,trial(http:// in patients with localized advanced or metastatic NSCLC with EGFR-activated mutations, assessed the efficacy and safety of Vizimpro relative to AstraZeneca's first-generation EGFR target-to-
drug (http:// Iressa for first-line therapy(PFS) 　　The study data showed that the Vizimpro treatment group achieved a statistically significant and clinically significant extension of PFS (14.7 months vs 9.2 months) compared to the Iressa treatment group, and a 41% significant reduction in the risk of death or disease progression, reaching the main endpoint of the study 　　In terms of safety
the most common adverse reactions in the Vizimpro treatment group included: diarrhea, rash, enteritis, stomatitis, loss of appetite, dry skin, weight loss, hair loss, cough, itching 　　Vizimpro treatment group in 27% of patients had severe adverse reactions, the most common serious adverse reactions were diarrhea and interstitial lung disease